已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Successful Treatment of Patients With Refractory PLA2R-Associated Membranous Nephropathy With Obinutuzumab: A Report of 3 Cases

医学 美罗华 奥比努图库单抗 膜性肾病 CD20 肾病综合征 免疫学 内科学 抗体 胃肠病学 肾小球肾炎 肾
作者
Nattawat Klomjit,Fernando C. Fervenza,Ladan Zand
出处
期刊:American Journal of Kidney Diseases [Elsevier BV]
卷期号:76 (6): 883-888 被引量:107
标识
DOI:10.1053/j.ajkd.2020.02.444
摘要

Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, has been shown to be an effective therapy in treatment of patients with MN associated with M-type phospholipase A2 receptor (PLA2R) antibodies. Despite its effectiveness, up to 40% of patients may fail to respond to rituximab, which may be related to higher PLA2R antibody titers. Obinutuzumab, a type II anti-CD20 depleter, has been shown to produce a more profound CD20 depletion and be more efficacious in treating certain hematologic malignancies compared with rituximab. We report 3 patients with PLA2R-associated MN for whom rituximab failed to induce immunologic or clinical remisison, but who were successfully treated with obinutuzumab. Obinutuzumab resulted in complete immunologic remission in all 3 cases and was followed by partial remission in 2 of the cases. Obinutuzumab appears to be a promising treatment strategy for PLA2R-associated MN that fails to respond to rituximab. Membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. Rituximab, a type I anti-CD20 antibody, has been shown to be an effective therapy in treatment of patients with MN associated with M-type phospholipase A2 receptor (PLA2R) antibodies. Despite its effectiveness, up to 40% of patients may fail to respond to rituximab, which may be related to higher PLA2R antibody titers. Obinutuzumab, a type II anti-CD20 depleter, has been shown to produce a more profound CD20 depletion and be more efficacious in treating certain hematologic malignancies compared with rituximab. We report 3 patients with PLA2R-associated MN for whom rituximab failed to induce immunologic or clinical remisison, but who were successfully treated with obinutuzumab. Obinutuzumab resulted in complete immunologic remission in all 3 cases and was followed by partial remission in 2 of the cases. Obinutuzumab appears to be a promising treatment strategy for PLA2R-associated MN that fails to respond to rituximab.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
syvshc的应助被科研通管家采纳,获得10
刚刚
ket的应助被科研通管家采纳,获得10
刚刚
alex的应助被科研通管家采纳,获得10
刚刚
爆米花的应助被科研通管家采纳,获得10
刚刚
情怀的应助被科研通管家采纳,获得10
刚刚
syvshc的应助被科研通管家采纳,获得10
1秒前
Akim的应助被刻苦灯泡采纳,获得10
2秒前
diligent完成签到,获得积分10
2秒前
2秒前
hehe发布了新的文献求助10
3秒前
XiaohuaTu完成签到 ,获得积分10
4秒前
hyeseongu完成签到,获得积分20
5秒前
李爱国的应助被坚定的依琴采纳,获得10
5秒前
fangzhi完成签到,获得积分10
7秒前
hyeseongu发布了新的文献求助10
7秒前
8秒前
玛卡巴卡完成签到,获得积分10
8秒前
chenchen完成签到,获得积分10
8秒前
明理溪流完成签到,获得积分10
9秒前
Mm完成签到,获得积分20
9秒前
菜根谭完成签到 ,获得积分10
10秒前
刻苦的若云完成签到 ,获得积分10
13秒前
雪满头的应助被che采纳,获得10
14秒前
shoyoyo完成签到 ,获得积分10
17秒前
aimynora完成签到 ,获得积分10
17秒前
万寿宫人发布了新的文献求助10
18秒前
木雨完成签到 ,获得积分10
18秒前
omo完成签到 ,获得积分10
20秒前
23秒前
ZZY完成签到,获得积分10
27秒前
贪玩的梦容完成签到,获得积分10
27秒前
刻苦灯泡发布了新的文献求助10
28秒前
科研通AI6.3的应助被dpcrel采纳,获得10
30秒前
lin完成签到,获得积分10
30秒前
风趣青筠完成签到,获得积分10
31秒前
逮劳完成签到 ,获得积分10
34秒前
OK发布了新的文献求助10
40秒前
Newky完成签到 ,获得积分10
41秒前
44秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194894
求助须知:如何正确求助?哪些是违规求助? 9580685
关于积分的说明 21872290
捐赠科研通 7794613
什么是DOI,文献DOI怎么找? 3437801
关于科研通互助平台的介绍 2561143
邀请新用户注册赠送积分活动 2484511